Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Daumke, Oliver Prof. Dr. (1) Franke, Vedran Dr. (1) Hübner, Norbert Prof. Dr. (1) Janz, Martin Dr. (9) Kolesnichenko, Marina Dr. (1) Patone, Giannino Dr. (1) Scheidereit, Claus Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Selbach, Matthias Prof. Dr. (1) Specker, Edgar Dr. (1) von Kries, Jens Peter Dr. (1) Wollert-Wulf, Brigitte (1) (-) Mathas, Stephan Dr. (14) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) 2004 (2) 2005 (2) 2006 (4) 2007 (3) 2008 (4) 2009 (3) 2010 (3) (-) 2011 (4) 2012 (1) 2013 (1) 2014 (2) (-) 2015 (5) 2016 (2) (-) 2017 (3) 2018 (1) (-) 2019 (2) 2020 (2) 2021 (3) 2022 (4) 2023 (8) 2024 (1) AG Müller/Dechend (ECRC) (1) Bioinformatics and Omics Data Science (1) (-) Biology of Malignant Lymphomas (14) Cancer Genetics and Cellular Stress Responses (1) Developmental Biology / Signal Transduction (2) Genetics and Genomics of Cardiovascular Diseases (2) Hypertension-caused End-Organ Damage (1) Hypertension-Mediated End-Organ Damage (1) In Situ Structural Biology (1) Integrative Vascular Biology (1) Molecular Immunology and Gene Therapy (1) Myology (2) Proteome Dynamics (1) Structural Biology of Membrane-Associated Processes (5) Systems Biology of Gene Regulatory Elements (2) Translational Bioinformatics (1) 14 Results: Active Filter: Mathas, Stephan Dr.Biology of Malignant Lymphomas2011201520172019 Sort: Result score Newest to oldest Oldest to newest June 01, 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz December 01, 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert Pagination Current page 1 Page 2 Next page Next › Last page Last »
November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas
August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf
April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas
July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz
December 01, 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann
January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert